Key Takeaways
- Revenue crosses INR1,000 crores in H1, a milestone driven by improved cost of goods sold and controlled operational expenses, though Q2 saw one-off costs that compressed margins sequentially.
- Volume growth is negative, price growth is the engine: Domestic volume growth was negative from April to September per Pharma Trac, while price growth ran at 4.9% for H1 after a deliberate strategy shift away from the old "most economical" pricing model.
- Portfolio de-risking is working: Dependency on the top three brands fell from ~50% to 44%, and seven brands in the INR50-100 crore range are being nurtured as the next growth layer.
- Management refuses all forward guidance: EBITDA margin, PCPM targets, cost savings, and brand-level market sizing were all declined, with the explicit statement that management has decided not to give any outlook.
- What to watch next half: Whether the October volume recovery signal sustains, the pace at which the seven mid-scale brands convert to the INR100 crore club, and how the consolidation phase for the 400-500 recently added MRs translates into productivity.
Domestic Business: Price vs Volume
- Volume contraction: Pharma Trac data shows negative volume growth from April through September, with market corrections in antibiotics and ORS following a post-COVID upsurge. October showed the first positive sign.
- Price growth fills the gap: H1 price growth was 4.9%, with Q1 at 6.1% and Q2 around 4%+. New product growth contributed only 0.8%, so the overall 5.8% domestic growth is overwhelmingly price-led.
- Strategy pivot on pricing: FDC moved away from its historical "most economical" pricing strategy because it became unworkable post-COVID with cost increases and China supply issues. The company has beaten the market by almost 5% during this turmoil.
- Consolidation over expansion: After adding 400-500 MRs through two divisional expansions, the company has been in a consolidation phase for 1.5 years, giving space for the new field force to become productive. No new MR hiring or divisionalization is planned in the near future; the phase continues for another 6 months, then gets reviewed.
- Geographic push eastward: Minor expansions continue, with a new focus on penetrating Bihar, Orissa, and then West Bengal. [13-14]
Tikkha: "We probably have moved on from that strategy because it was not a workable module for us."
Brand Portfolio & New Launches
- Flagship brands hit new highs: Electral, Zifi, and Enerzal all reached new peaks in H1. Zifi CV alone commands 49% market share in its category.
- The next INR100 crore candidates: Seven brands sit in the INR50-100 crore range: Zifi CV, Vitcofol, Zathrin, Zocon, Zifi-O, Simyl MCT, and Flemiclav. Management expects a couple of these to cross the INR100 crore mark in the near future. Zocon (derma division) grew 30%+.
- Top-brand dependency falling: The top three brands' share of the portfolio dropped from ~50% to 44% in the current half, a deliberate broadening outcome.
- New launches restarting after a long pause: The company refrained from launching new brands since 2019 pre-COVID to focus on consolidation. With negative volume growth now a reality, strategy is shifting: management will look at some new introductions. Line extensions already launched include Zifi CV, Zifi O, Electral Z, and Enerzal in pet bottles. [14-15]
- Nutrica basket: The nutraceuticals division (Nutrica) operates in a INR2,400+ crore covered market with a 3.9% share; the company will work on it per its operational plan.
Tikkha: "I am happy to share maybe in the first half, we have done really well. Our market shares have definitely improved in Zifi CV and we control almost 49% of the market in that particular category."
Export Business
- Growth trajectory: Export business is growing quarter-on-quarter at a double-digit rate, with no one-off orders distorting the picture. The momentum is described as healthy and positive.
- Geographic spread widening: The company will continue to increase its footprint in non-US markets, particularly Europe, Asia-Pacific, and some African regions. The stated aim is for exports to become a very sizable contributor to total revenue. [8-9]
- US ophthal focus: The right to win in the US market rests on the ophthalmic business, where FDC has been present for quite some time, understands the space well, and is performing well with its business partners.
- Investment commitment: Management confirmed it will continue to invest in the export business, which it sees as having a lot of future growth potential.
- Domestic-export comparison off limits: When asked to compare profitability or RoCE between export and domestic businesses, management declined, calling it a very difficult question and stating the two complement each other in the overall scheme of things.
Bhatt: "Let's not get into the comparison of domestic versus export. But they both are complementing each other in the overall scheme of things."
Margins & Costs
- H1 profitability drivers: Improved cost of goods sold and relatively low operational expenses were the primary drivers of increased profitability in the first half.
- Q2 EBITDA margin dipped sequentially: Q1 is the predominant season with normalized sales generally high, bringing incremental profitability, so Q1 EBITDA margin tends to be higher than other quarters. Q2 EBITDA margin is also healthy; management requests looking at margin on a half-yearly basis because the business pattern does not remain the same every quarter.
- One-off expenses in Q2: Two ANDA filings during H1 incurred large filing fees, major scheduled maintenance repairs fell coincidentally in Q2, and registration funds and certain fees added to the expense load. These are investment in nature; if neutralized, the expense picture normalizes. [4-5]
- Cost optimization is incremental, not transformational: There is no low-hanging fruit. Areas of improvement include operational fields in manufacturing (optimizing yields and efficiency), the marketing side, and corporate support expenditures. Operational expenditure is now curtailed and not growing higher than revenue growth.
- Investment spend will continue: Certain investment expenditures in R&D will continue in the coming period; the company is growing and will invest in businesses.
Bhatt: "If you say anything like a low-hanging fruit, there is nothing easy in terms of the cost optimization."
Productivity & Capital Allocation
- PCPM improving: PCPM improved to INR3.89 lakhs in H1 from ~INR3 lakhs after two major divisional expansions had brought it down. The company is looking to take it further, but no specific target number was given because the market is very dynamic and volume growth is negative.
- Capital allocation is domestic-first: The company is domestic-centric, with over 80% of revenue from the domestic business. Cash generated from the India business is not primarily used to invest in export markets; the company is built on the domestic business.
- Buyback completed: The board approved a buyback of 31 lakh equity shares at INR500 per share; the process and payout were concluded during Q2.
- Corporate office capex: A new corporate office is under construction, expected to be ready by the end of the next calendar year, with expenditure spilling over into the next financial year.
- No demerger: Management confirmed there are no plans to demerge the pharma and food divisions.
Tikkha: "In such a situation, it is very difficult to predict and to give any guidance about what would be the possible growth. We are keeping our fingers crossed."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Field force consolidation | Continue current phase, then review | Another 6 months or so |
| New brand introductions | Shift strategy to launch some new introductions after pausing since 2019 | No date (strategy shift confirmed) |
| Corporate office completion | New corporate office ready | End of next calendar year |
| Export footprint expansion | Increase footprint in Europe, Asia-PAC, Africa; exports to become sizable contributor | No date (ongoing endeavor) [8-9] |
| Quarterly earnings calls | Continue as a norm | Management confirmed: "Yes, certainly. Noted." |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Consolidated revenue | ₹486 cr, +9% YoY |
| H1 FY24 consolidated revenue | ₹1,023 cr, +9% YoY; first time crossing ₹1,000 cr landmark |
| Domestic business revenue | ₹391 cr, +6% YoY |
| Export formulation revenue | ₹76 cr, +33% YoY |
| API business revenue | ₹19 cr, +2% YoY |
| Consolidated EBITDA | ₹76 cr, +13% YoY |
| H1 FY24 consolidated EBITDA | ₹198 cr, +36% YoY |
| Consolidated profit after tax | ₹70 cr, +35% YoY |
| H1 FY24 consolidated profit after tax | ₹180 cr, +47% YoY |
| EBITDA margin (H1 FY24, year-to-date) | ~19%, slightly above 19% on a consolidated basis |
| Domestic business volume growth (H1 FY24) | Stagnated |
| Domestic business price growth (H1 FY24) | 4.9% |
| Domestic business new product growth (H1 FY24) | 0.8% |
| Export formulation revenue as a share of total revenue | ~13% |
| Total field force | ~4,800 including managers |
| PCPM (H1 FY24) | ₹3.89 lakhs |
| Top 3 brands dependency (H1 FY24) | 44% of revenue, down from ~50% a couple of years back |
| Zifi CV market share | 49% in its category |
| Zifi-O growth rate (IQVIA, first 6 months) | 16% |
| Flemiclav growth rate | 31% |
| Zefu growth rate | 14% |
| Mum-Mum growth rate | 33% |
| Electral brand size (IQVIA) | Crossed ₹400 cr |
| Zifi brand size (IQVIA) | Crossed ₹300 cr |
| Enerzal brand size | Close to ₹200 cr |
| Enerzal market share | ~40% |
| Nutrica basket addressable market | ₹2,400+ cr, with 3.9% market share |
| Regular maintenance capex | ~₹50 cr annually |
| Buyback | 31 lakh shares at ₹500 per share, concluded during Q2 |